Encouraged by research linking a gene with bone mass density, Roche Palo Alto plans to develop what the Swiss company hopes will become the first molecular diagnostic for osteoporosis risk, SNPtech Pharmacogenomics Reporter has learned.

The company said it also hopes to develop a therapeutic that would target the product of that gene, Alox15, and help delay or even reverse the onset of osteoporosis — a disease that costs US health-care facilities $17 billion a year to treat, according to the National Osteoporosis Foundation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.